Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1635 1636
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18129923 | G PROTEIN-COUPLED RECEPTOR 75 (GPR75) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17845535 | USE OF SARAF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 17810022 | METHODS FOR THE TREATMENT OF EPILEPSY | Non-Final OA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 17597351 | METHODS FOR THE TREATMENT OF EPILEPSY | Final Rejection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 17974805 | TOPOLOGIES OF SYNTHETIC GENE CIRCUIT FOR OPTIMAL FOLD CHANGE ACTIVATION | Final Rejection | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED |
| 18306511 | Method and Reagents for Reprogramming Endothelial Cells | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17995568 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 18248363 | HOMOGENEOUS BETA-1,3-GLUCAN/NUCLEIC ACID COMPLEXES AND USE THEREOF | Non-Final OA | The University of Kitakyushu |
| 18027476 | FOXP3S-PROMOTING MORPHOLINOS | Non-Final OA | THE TRUSTEES OF INDIANA UNIVERSITY |
| 18467442 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | Final Rejection | UNIVERSITY OF ROCHESTER |
| 17835671 | NUCLEIC ACID CONSTRUCTS ENCODING KALLIKREIN-2 FUSION PROTEIN AND VECTORS, PREPARATIONS OF CELLS, AND METHODS OF USE THEREOF | Final Rejection | Janssen Biotech, Inc. |
| 18734879 | Guide Strand Library Construction and Methods of Use Thereof | Non-Final OA | Pioneer Biolabs, LLC |
| 17755165 | NUCLEIC ACID DELIVERY ENHANCER | Final Rejection | TOKYO UNIVERSITY OF SCIENCE FOUNDATION |
| 18175394 | ENGINEERED MICROALGAE FEED TO IMPROVE HONEY BEE PATHOGEN RESISTANCE AND NUTRITION | Non-Final OA | The United States of America, as represented by The Secretary of Agriculture |
| 18311789 | METHOD OF TREATING DUCHENNE MUSCULAR DYSTROPHY | Non-Final OA | BioMarin Pharmaceutical Inc. |
| 17214436 | IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF | Non-Final OA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC |
| 17262342 | GENE EDITING OF ANTICOAGULANTS | Final Rejection | TOOLGEN INCORPORATED |
| 18249036 | COMPOSITION FOR TREATING RETINAL OR CHOROIDAL DISEASES, CONTAINING ACTA2 INHIBITOR AS ACTIVE INGREDIENT | Non-Final OA | AMC SCIENCES CO., LTD |
| 18040803 | NUCLEIC ACID THERAPY FOR DIFFERENTIAL MODULATION OF HOST MICROFLORA | Non-Final OA | Michael STALHAMER |
| 18098883 | SYNTHETIC RNA FRAGMENT AND ITS USES FOR RNA-DEPENDENT AMPLIFICATION | Non-Final OA | MELLO BIOTECH TAIWAN CO., LTD. |
| 17601934 | HYBRID PROMOTERS FOR MUSCLE EXPRESSION | Final Rejection | UNIVERSITE D'EVRY VAL D'ESSONNE |
| 18000197 | Biomarkers Related to Oral Squamous Cell Carcinoma and Methods of Diagnosis and Treatment Thereof | Non-Final OA | QINGDAO MEDINTELL BIOMEDICAL CO., LTD |
| 17985963 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF GAP JUNCTION PROTEIN BETA 2 (GJB2) | Non-Final OA | Korro Bio, Inc. |
| 17299186 | METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY | Final Rejection | TAKEDA PHARMACEUTICALS U.S.A., INC. |
| 17604332 | STABLE TARGETED INTEGRATION | Non-Final OA | Sigma-Aldrich Co. LLC |
| 17800806 | ARCHAEAL PYRROLYSYL TRNA SYNTHETASES FOR ORTHOGONAL USE | Non-Final OA | European Molecular Biology Laboratory |
| 17201763 | DEVICES AND METHODS FOR SINGLE CELL ANALYSIS | Non-Final OA | Quantumcyte, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy